Abstract：
UNASSIGNED: To assess the management of patients with congenital nasolacrimal duct obstruction (CNLDO) in a paediatric population and review the long-term outcomes over a 5-year interval, with particular emphasis on the difference between patients with trisomy 21 and those without trisomy 21.
UNASSIGNED: This single-centre, retrospective, cross-sectional, case review study included patients suffering from CNLDO at Alder Hey Children\'s Hospital NHS foundation Trust. Patients were divided into two groups: Non-trisomy 21 and trisomy 21. Patients were followed-up for a 60-month interval. Patients aged <12 months at the time of surgery, patients with <60 months of follow-up data and patients with acquired nasolacrimal duct obstruction were excluded. The main outcome measures were discharge rates in patients undertaking primary intervention with syringe and probe (S&P), number of patients requiring further treatment with lacrimal intubation or dacryocystorhinostomy (DCR) and overall symptom-free periods post-treatment.
UNASSIGNED: Ninety-three patients (142 eyes) were included. The mean number of surgical interventions was 1.53 ± 0.65. The mean interval between the 1st and 2nd intervention was 15.54 ± 16.33 months. There was a trend towards greater success rates non-trisomy 21 patients versus patients with trisomy 21 (p = 0.1352). The average symptom-free period after the final intervention was 44.31 ± 20.68 months, significantly longer in the non-trisomy 21 group compared to the trisomy 21 group (p = 0.0074).
UNASSIGNED: The overall success rate after primary S&P was 55.9%. Our results suggest that in trisomy 21 patients suffering from CNLDO, a one-stage intervention with primary monocanalicular intubation should be considered instead of sequential approach.
UNASSIGNED: This single-centre, retrospective, cross-sectional, case review study included patients suffering from CNLDO at Alder Hey Children\'s Hospital NHS foundation Trust. Patients were divided into two groups: Non-trisomy 21 and trisomy 21. Patients were followed-up for a 60-month interval. Patients aged <12 months at the time of surgery, patients with <60 months of follow-up data and patients with acquired nasolacrimal duct obstruction were excluded. The main outcome measures were discharge rates in patients undertaking primary intervention with syringe and probe (S&P), number of patients requiring further treatment with lacrimal intubation or dacryocystorhinostomy (DCR) and overall symptom-free periods post-treatment.
UNASSIGNED: Ninety-three patients (142 eyes) were included. The mean number of surgical interventions was 1.53 ± 0.65. The mean interval between the 1st and 2nd intervention was 15.54 ± 16.33 months. There was a trend towards greater success rates non-trisomy 21 patients versus patients with trisomy 21 (p = 0.1352). The average symptom-free period after the final intervention was 44.31 ± 20.68 months, significantly longer in the non-trisomy 21 group compared to the trisomy 21 group (p = 0.0074).
UNASSIGNED: The overall success rate after primary S&P was 55.9%. Our results suggest that in trisomy 21 patients suffering from CNLDO, a one-stage intervention with primary monocanalicular intubation should be considered instead of sequential approach.
摘要：
■评估儿科人群先天性鼻泪管阻塞（CNLDO）患者的治疗，并回顾5年间隔的长期结局，特别强调21三体和没有21三体的患者之间的差异。
■这种单中心，回顾性,横截面,病例回顾研究包括AlderHey儿童医院NHS基金会信托基金的CNLDO患者。患者分为两组：非三体性21和三体性21。患者随访60个月。手术时年龄<12个月的患者，随访数据<60个月的患者和获得性鼻泪管阻塞的患者被排除在外.主要结局指标是接受注射器和探针（S＆P）主要干预的患者的出院率，需要进行泪道插管或泪囊鼻腔造口术（DCR）进一步治疗的患者人数以及治疗后的总体无症状期。
■93例患者（142只眼）。手术干预的平均次数为1.53±0.65。第一次和第二次干预之间的平均间隔为15.54±16.33个月。与21三体患者相比，非21三体患者的成功率有更高的趋势（p=0.1352）。最终干预后的平均无症状期为44.31±20.68个月，与21三体组相比，非21三体组明显更长（p=0.0074）。
■初次标准普尔后的总体成功率为55.9％。我们的结果表明，在患有CNLDO的21三体患者中，应考虑采用原发性单管段插管的一阶段干预,而不是序贯方法.
■这种单中心，回顾性,横截面,病例回顾研究包括AlderHey儿童医院NHS基金会信托基金的CNLDO患者。患者分为两组：非三体性21和三体性21。患者随访60个月。手术时年龄<12个月的患者，随访数据<60个月的患者和获得性鼻泪管阻塞的患者被排除在外.主要结局指标是接受注射器和探针（S＆P）主要干预的患者的出院率，需要进行泪道插管或泪囊鼻腔造口术（DCR）进一步治疗的患者人数以及治疗后的总体无症状期。
■93例患者（142只眼）。手术干预的平均次数为1.53±0.65。第一次和第二次干预之间的平均间隔为15.54±16.33个月。与21三体患者相比，非21三体患者的成功率有更高的趋势（p=0.1352）。最终干预后的平均无症状期为44.31±20.68个月，与21三体组相比，非21三体组明显更长（p=0.0074）。
■初次标准普尔后的总体成功率为55.9％。我们的结果表明，在患有CNLDO的21三体患者中，应考虑采用原发性单管段插管的一阶段干预,而不是序贯方法.
